Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 93.34% is 75% above its 5-year average of 53.32%, near the high end of its 5-year range (0.00%–97.39%).
0.21% above its 12-month average of 93.14%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 94.60%.
GROSS MARGIN
93.34%
GROSS MARGIN AVG TTM
93.14%
GROSS MARGIN AVG 3Y
93.31%
GROSS MARGIN AVG 5Y
53.32%
GROSS MARGIN AVG 10Y
42.99%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.21%
CURRENT VS 3Y AVG
+0.03%
CURRENT VS 5Y AVG
+75.05%
CURRENT VS 10Y AVG
+117.10%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+126.53%
vs the sector median at left
Krystal Biotech, Inc.
Market Cap
$9.63B
Gross Margin
93.34%
TTM Avg
93.14%
3Y Avg
93.31%
5Y Avg
53.32%
Market Cap
$9.66B
Gross Margin
30.31%
TTM Avg
29.43%
3Y Avg
29.32%
5Y Avg
29.12%
Market Cap
$9.87B
Gross Margin
51.05%
TTM Avg
45.19%
3Y Avg
47.81%
5Y Avg
50.44%
Market Cap
$9.93B
Gross Margin
51.90%
TTM Avg
52.87%
3Y Avg
53.77%
5Y Avg
54.60%
Market Cap
$10.03B
Gross Margin
14.14%
TTM Avg
15.74%
3Y Avg
16.11%
5Y Avg
16.54%
Market Cap
$9.21B
Gross Margin
46.69%
TTM Avg
47.45%
3Y Avg
49.39%
5Y Avg
49.15%
Market Cap
$10.13B
Gross Margin
66.48%
TTM Avg
69.16%
3Y Avg
69.73%
5Y Avg
70.75%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | $9.63B | 93.34% | 93.14% | 93.31% | 53.32% |
| Vaxcyte, Inc. (PCVX)vs › | $9.63B | 0.00% | 0.00% | 0.00% | 0.00% |
| Henry Schein, Inc. (HSIC)vs › | $9.66B | 30.31% | 29.43% | 29.32% | 29.12% |
| Repligen Corporation (RGEN)vs › | $9.87B | 51.05% | 45.19% | 47.81% | 50.44% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 51.90% | 52.87% | 53.77% | 54.60% |
| Insulet Corp. (PODD)vs › | $9.33B | 71.08% | 70.71% | 67.87% | 67.39% |
| The Ensign Group, Inc. (ENSG)vs › | $10.03B | 14.14% | 15.74% | 16.11% | 16.54% |
| Bruker Corporation (BRKR)vs › | $9.21B | 46.69% | 47.45% | 49.39% | 49.15% |
| Align Technology, Inc. (ALGN)vs › | $10.13B | 66.48% | 69.16% | 69.73% | 70.75% |
| ImmunityBio, Inc. (IBRX)vs › | $10.15B | 94.63% | 99.67% | 99.84% | 99.89% |
Gross Margin
93.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 94.60% |
| 2026-03-31 | 94.57% |
| 2025-12-31 | 89.81% |
| 2025-09-30 | 94.21% |
| 2025-06-30 | 92.54% |
| 2025-03-31 | 94.30% |
| 2024-12-31 | 94.57% |
| 2024-09-30 | 92.03% |
| 2024-06-30 | 91.45% |
| 2024-03-31 | 94.65% |
| 2023-12-31 | 89.61% |
| 2023-09-30 | 97.39% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 100.00% |
| 2018-12-31 | 100.00% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
